Corient Private Wealth
KPTI icon

Corient Private Wealth’s Karyopharm Therapeutics KPTI Stock Holding History

Corient Private Wealth’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,039
Closed -$10K – 2955
2025
Q4 		$10K Buy
+10,039
New +$61.4K ﹤0.01% 2709
2025
Q1 		– Sell
-1,367
Closed -$13.9K – 2372
2024
Q4 		$13.9K Sell
1,367
-39
-3% -$472 ﹤0.01% 2315
2024
Q3 		$17.5K Buy
1,406
+499
+55% +$6.2K ﹤0.01% 2434
2024
Q2 		$11.8K Sell
907
-20
-2% -$331 ﹤0.01% 2303
2024
Q1 		$21K Sell
927
-6
-0.6% -$105 ﹤0.01% 2261
2023
Q4 		$12.1K Buy
+933
New +$12.6K ﹤0.01% 2232

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Corient Private Wealth's KPTI Position: Q1 2026 in Review

Corient Private Wealth sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 10,039 shares — an estimated $10K sold.

Corient Private Wealth first reported a position in KPTI in Q4 2023 and held it in 6 quarters. The position peaked at $21K in Q1 2024. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Corient Private Wealth reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 10,039 Karyopharm Therapeutics shares in Q1 2026, an estimated $10K.
  • Corient Private Wealth first reported a position in Karyopharm Therapeutics in Q4 2023 and held it in 6 quarters.
  • Corient Private Wealth's Karyopharm Therapeutics position peaked at $21K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.